NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
TCRT
Alaunos Therapeutics, Inc.
There isn't enough reported data to score TCRT yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
TCRT Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Unavailable | |
| Unavailable |
TCRT's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
TCRT PE Valuation
TCRT has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
TCRT Forward outlook
There aren't enough analyst estimates for TCRT to show an outlook.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over TCRT on earnings quality, reporting a profit while its opponent remains loss making.
TCRT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.90 | +$0.51 |
| Q1 2026 | -$2.12 | +$0.37 |
| Q4 2025 | -$2.20 | +$0.72 |
| Q3 2025 | -$2.26 | +$4.25 |
| Q2 2025 | -$2.41 | +$9.40 |
| Q1 2025 | -$2.49 | +$14.61 |
| Q4 2024 | -$2.92 | +$19.08 |
| Q3 2024 | -$6.51 | +$15.99 |
TCRT is still losing money, but far less than before: $1.90 per share over the past year, against $105.00 at its worst in early 2020.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over TCRT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO's operating margin was 34% last quarter, down 9 points from the same quarter a year ago, near the bottom of its range since 2019.
TCRT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $3K | -25% |
| Q1 2025 | $2K | +100% |
| Q4 2024 | $4K | +300% |
| Q2 2024 | $4K | 0% |
| Q4 2023 | $1K | -91% |
| Q3 2022 | $2.9M | +631% |
TCRT's revenue has slid since its 2022 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -30233% | -11358 points |
| Q1 2025 | -54600% | +119600 points |
| Q4 2024 | -18875% | +776025 points |
| Q2 2024 | -29150% | +170400 points |
| Q1 2024 | -174200% | N/A |
| Q4 2023 | -794900% | -717436 points |
| Q2 2023 | -199550% | N/A |
| Q4 2022 | -77464% | N/A |
TCRT's operating margin was −30233% last quarter, up 143967 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
TCRT has the stronger cash trend. Its trailing FCF is up 93% versus its history, compared with NVO at down 14%.
TCRT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$300K | +$401K |
| Q1 2026 | -$1M | -$259K |
| Q4 2025 | -$553K | +$39K |
| Q2 2025 | -$701K | +$980K |
| Q1 2025 | -$772K | +$1.1M |
| Q4 2024 | -$592K | +$6.8M |
| Q3 2024 | -$781K | +$5.6M |
| Q2 2024 | -$1.7M | +$5.5M |
TCRT has burned cash in almost every quarter: −$3M over the past year, against −$4M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over TCRT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
TCRT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +25% | +483K shares |
| 1 year | +45% | +755K shares |
| 3 years | +52% | +833K shares |
| 5 years | +70% | +1M shares |
| Available history | +114% | +1.3M shares |
TCRT has 2M diluted shares, up 45% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q4 2022 | — |
| Q4 2019 | $283,000 |
| Q3 2019 | — |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
TCRT Net Leverage
TCRT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
TCRT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.5 | Neutral |
| Stochastic | 28.6 | Neutral |
TCRT's weekly RSI is 45 (neutral) and its Stochastic is 29 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
TCRT PE vs Healthcare Sector
| Metric | TCRT | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
TCRT has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
TCRT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.61 | 0.6% above |
| 20 week MA | $1.73 | 6.4% below |
| 50 week MA | $2.43 | 33% below |
| 100 week MA | $2.50 | 35% below |
| 200 week MA | $17.4 | 91% below |
TCRT has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 91% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over TCRT on returns for 2026, with the stronger performance.
TCRT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $772.5 | $432.0 | -44% |
| 2021 | $432.0 | $189.0 | -56% |
| 2022 | $189.0 | $88.2 | -53% |
| 2023 | $88.2 | $10.6 | -88% |
| 2024 | $10.6 | $1.84 | -83% |
| 2025 | $1.84 | $3.23 | +76% |
| 2026 YTD | $3.23 | $1.62 | -50% |
TCRT has finished lower in five of the last six years. It's down 50% so far in 2026.